TABLE 2.
Comparison | miRNA | AUC | Sensitivity | Specificity | p-value |
---|---|---|---|---|---|
NT x BC | miR-142-5p | 0.7434 | 66.67 | 96.15 | 0.0005 |
miR-150-5p | 0.8108 | 91.67 | 85.71 | <0.0001 | |
miR-320a-3p | 0.9009 | 74.19 | 81.48 | <0.0001 | |
miR-4433b-5p | 0.8462 | 65.38 | 81.48 | <0.0001 | |
miR-150-5p + miR-320a-3p panel | 0.8929 | 100.0 | 67.86 | <0.0001 | |
miR-142-5p + miR-320a-3p panel | 0.7232 | 89.29 | 46.43 | 0.0041 | |
miR-320a-3p + miR4433b-5p | 0.9121 | 100.0 | 78.57 | < 0.0001 | |
miR-142-5p + miR-320a-3p + miR-4433b-5p panel | 0.9084 | 100.0 | 78.57 | <0.0001 | |
miR-150-5p + miR-320a-3p + miR-4433b-5p panel | 0.9075 | 100.0 | 78.57 | <0.0001 | |
miRNAs complete panel* | 0.8982 | 78.57 | 100.0 | <0.0001 | |
NT x LA | miR-142-5p | 0.7368 | 61.11 | 100.0 | 0.0063 |
miR-150-5p | 0.8797 | 94.44 | 85.71 | <0.0001 | |
miR-320a | 0.9125 | 70.00 | 92.59 | < 0.0001 | |
miR-4433b-5p | 0.8482 | 68.75 | 81.48 | 0.0001 | |
miR-150-5p + miR-320a-3p panel | 0.9079 | 89.29 | 78.95 | <0.0001 | |
miR-142-5p + miR-320a-3p + miR-4433b-5p panel | 0.9082 | 78.57 | 100.0 | <0.0001 | |
miR-150-5p + miR-320a-3p + miR-4433b-5p panel | 0.9056 | 78.57 | 100.0 | <0.0001 | |
miRNAs complete panel* | 0.8929 | 78.57 | 100.0 | <0.0001 | |
NT x TNBC | miR-142-5p | 0.7571 | 77.78 | 100.0 | 0.0170 |
miR-150-5p | 0.6473 | -- | -- | 0.2092 | |
miR-320a | 0.8799 | 63.64 | 92.59 | 0.0003 | |
miR-4433b-5p | 0.8429 | 60.00 | 88.89 | 0.0015 | |
miR-150-5p + miR-320a-3p panel | 0.9152 | 92.86 | 75.00 | 0.0004 | |
miR-142-5p + miR-320a-3p + miR-4433b-5p panel | 0.9008 | 78.57 | 100.0 | 0.0003 | |
miR-150-5p + miR-320a-3p + miR-4433b-5p panel | 0.9241 | 75.00 | 100.0 | 0.0003 | |
miRNAs complete panel* | 0.9240 | 75.00 | 100.0 | 0.0003 |
(*): The four miRNAs were evaluated together. In bold and underlined are the highest AUC values for the group comparison. Only AUC>0.7 is presented, except for NT x TN, using miR-150-5p. Sensitivity and specificity are presented as percentages (%). BC, breast cancer; NT, adjacent non-tumor tissue; LA, luminal A; TNBC, triple-negative breast cancer; and (--) not evaluated.